MODERNA US, INC.

Moderna US, Inc. specializes in the manufacturing of mRNA-based pharmaceutical preparations, with a demonstrated focus on pediatric and adult COVID-19 vaccines. The company leverages advanced biomanufacturing platforms to produce highly specialized immunotherapeutic agents under stringent cGMP conditions, ensuring consistency, purity, and potency in large-scale production. Their technical expertise includes nucleotide sequence optimization, lipid nanoparticle formulation, cold chain logistics for mRNA therapeutics, and aseptic fill-finish operations. Moderna’s differentiation lies in its proprietary mRNA platform technology, enabling rapid development and scalable production of vaccines against emerging pathogens, with proven capability in meeting urgent public health demands. The contractor maintains a consistent relationship with the Department of Health and Human Services, delivering critical vaccine supply for national immunization efforts, particularly for pediatric and adult populations. Additionally, they support the Department of Veterans Affairs through the Federal Supply Schedule, providing pharmaceuticals for clinical use in veteran healthcare facilities. These engagements reflect a pattern of mission-critical, time-sensitive procurement aligned with public health preparedness and chronic care needs. The primary NAICS code 325412, Pharmaceutical Preparation Manufacturing, defines their core activity: the production of sterile, injectable biologics and vaccines using cutting-edge molecular biology and process engineering. Their vertical specialization is in infectious disease prophylaxis, with a clear emphasis on mRNA therapeutics—a rapidly evolving segment of biopharmaceutical innovation. This positions them as a key player in next-generation vaccine manufacturing for federal health security. Moderna US, Inc. is structured as a 2L entity headquartered in Princeton, New Jersey. While no government certifications are listed, their operations adhere to FDA regulatory standards for biological product manufacturing. Their geographic presence and federal engagement reflect a strategic alignment with national health infrastructure, serving as a reliable supplier for federally funded immunization programs.